Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IGM-7354 · 1 trial · 1 indication
Incidence of treatment-emergent AEs, SAEs, and DLT per NCI CTCAE v5.0
| Arm | Type | Description |
|---|---|---|
| IGM-7354 Single-Agent Dose Escalation | EXPERIMENTAL | IGM-7354 will be administered intravenously as a single agent. |
| IGM-7354 Single-Agent Dose Expansion Serial Biopsy | EXPERIMENTAL | IGM-7354 will be administered intravenously as a single agent and patients will undergo pre-treatment and on-treatment biopsies. |
| Name | Type | Description |
|---|---|---|
| IGM-7354 | DRUG | IGM-7354 is a PD-L1-targeted cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects |
Key Inclusion Criteria: * Age \> 18 years at time of signing ICF * ECOG Performance Status of 0 or 1 * Histologic or cytologic documentation of incurable, locally advanced or metastatic solid tumors for which standard therapies are not available, are no longer effective, are not tolerated, or have ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
IGM-7354 is an investigational small molecule being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development, having been evaluated in a completed trial for adults with relapsed and/or refractory cancer. The drug is not yet approved and remains under investigation.
IGM-7354 is being developed by IGM Biosciences, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol IGMS. IGM Biosciences is responsible for the clinical development of this investigational oncology drug.
IGM-7354 is in Phase 1 clinical development. A Phase 1 trial has been completed, which evaluated the drug in adults with relapsed and/or refractory solid tumors. The drug is investigational and has not received regulatory approval.
IGM-7354 has been studied in a Phase 1 clinical trial with the identifier NCT05702424, titled 'Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer.' This trial enrolled 14 participants with solid tumors in the United States and has been completed.
IGM-7354 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial in solid tumors. The drug remains in clinical development and has not been authorized for commercial use.